Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Baxter
Merck
Medtronic
Express Scripts

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR MINOCIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Minocin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00240513 ↗ Study Comparing Acne in Patients Taking Oral Minocycline to Patients Taking Minocycline Plus Topical Tretinoin Terminated Stiefel, a GSK Company Phase 4 2004-08-01 The use of oral antibiotics alone to treat inflammatory acne provides little to no long term therapeutic benefit. Acne relapse rates can be reduced by using topical tretinoin 0.01% in conjunction with minocycline, thereby increasing the therapeutic effect of the oral antibiotic.
NCT00240513 ↗ Study Comparing Acne in Patients Taking Oral Minocycline to Patients Taking Minocycline Plus Topical Tretinoin Terminated Derm Research @ 888 Inc. Phase 4 2004-08-01 The use of oral antibiotics alone to treat inflammatory acne provides little to no long term therapeutic benefit. Acne relapse rates can be reduced by using topical tretinoin 0.01% in conjunction with minocycline, thereby increasing the therapeutic effect of the oral antibiotic.
NCT00355459 ↗ A Prospective Clinical Study Assessing the Effects of Tetracycline Antibiotic on Tear Film and Tear Lipid Composition Within a Population of Patients Diagnosed With Blepharitis and Dry Eye Disease Withdrawn University of Texas Southwestern Medical Center N/A 2005-08-01 The purpose of this research project is to determine the effects of oral tetracycline such as Minocycline (Minocin) on tear film composition and tear lipid (meibomian gland secretions) characteristics in patients with chronic Blepharitis and associated dry eyes.
NCT00456677 ↗ Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma Completed State University of New York - Downstate Medical Center Phase 2 1996-06-01 Trial of effects of minocycline as "add-on" therapy to adults with asthma with a history of requiring at least one episode of oral steroid therapy to control the disease.
NCT00473083 ↗ Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer Completed Hoffmann-La Roche Phase 2 2009-01-01 The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach. Hypothesis: Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy with minocycline can prevent occurrence in 50% of these patients. Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80% of patients. Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring treatment with monotherapy intervention.
NCT00473083 ↗ Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer Completed British Columbia Cancer Agency Phase 2 2009-01-01 The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach. Hypothesis: Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy with minocycline can prevent occurrence in 50% of these patients. Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80% of patients. Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring treatment with monotherapy intervention.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Minocin

Condition Name

Condition Name for Minocin
Intervention Trials
Healthy 2
Autism Spectrum Disorder 2
Lung Cancer 2
Depression 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Minocin
Intervention Trials
Depressive Disorder 5
Depression 5
Lung Neoplasms 4
Syndrome 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Minocin

Trials by Country

Trials by Country for Minocin
Location Trials
United States 58
Canada 13
Germany 5
China 1
Austria 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Minocin
Location Trials
Texas 13
New York 7
North Carolina 5
Michigan 4
Missouri 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Minocin

Clinical Trial Phase

Clinical Trial Phase for Minocin
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Minocin
Clinical Trial Phase Trials
Completed 25
Terminated 4
Unknown status 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Minocin

Sponsor Name

Sponsor Name for Minocin
Sponsor Trials
National Cancer Institute (NCI) 11
M.D. Anderson Cancer Center 11
Innovative Medicines Initiative 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Minocin
Sponsor Trials
Other 60
Industry 14
NIH 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Medtronic
McKesson
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.